Fenben is an antiparasitic medication that has been used for a long time to treat parasitic worms in animals like horses. It has recently been shown that the medication can also be useful in fighting cancers as well. It has become known as the Joe Tippens Protocol after a man named Joe Tippens used it to cure his stage four pancreatic cancer which had spread to his stomach, neck, right lung and bladder. He was given three months to live by doctors but decided to try something different and he found that using fenben for humans along with curcumin and CBD cured his cancer.
A new scientific paper has revealed that fenbendazole, which is part of the benzimidazole family of drugs, possesses microtubule depolymerizing activity towards human cancer cells and has a potent antitumor effect in vivo and in vitro. The drug was able to disrupt the microtubules and reactivate p53 which is a gene that prevents cancer cells from developing. It also inhibited glucose uptake in cancer cells by downregulating GLUT transporters and hexokinase (HK II) which is important for glycolysis.
Moreover, the drug was able to depolymerize the microtubules of ovarian cancer cells which caused cell death in a dose-dependent manner. The researchers of this study suggest that fenbendazole has the potential to be a cancer therapy when used in combination with other therapeutic strategies like radiation, surgery, berberine and sodium dichloroacetate.
This research is just a further piece of evidence that supports the growing body of scientific literature that shows that anthelmintics, which are medications used to treat parasitic worms in animals, have a cancer-fighting capacity as well. The medications are typically well tolerated by animals and do not cause any major side effects. Nevertheless, Health Canada lists all of these medications for veterinary use only.
In the past, several peer-reviewed studies have shown that fenbendazole is a promising cancer treatment in mice. However, no peer-reviewed studies have been conducted to confirm that this is true in people as well. This prompted the researchers to investigate the effect of fenbendazole on human cancers.
The research showed that fenbendazole had a potent effect on human cancers in both in vitro and in vivo experiments. It exhibited moderate MT depolymerizing activity and had a significant antitumor effect in both in vivo and in vitro models. The drug also prevented the development of a xenograft in a mouse model.
The researchers also found that fenbendazole inhibited the growth of cancer cells in mice and did not influence normal cells. Furthermore, it was able to enhance the effects of other cancer treatments. The mice that were given fenbendazole in conjunction with radiation showed a greater reduction in tumor volume than did the mice that received only radiation. Three daily i.p. injections of fenbendazole was able to reduce the growth of EMT6 tumors in BALB/c mice to less than half their initial volume when combined with irradiation. fenben for humans